Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ORGS

Orgenesis Inc

Apr 19 • 04:00PM ET

0.5009

Dollar change -0.0112
Percentage change -2.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.10	Insider Own	16.07%	Shs Outstand	31.88M	Perf Week	1.60%
Market Cap	17.20M	Forward P/E	-	EPS next Y	-	Insider Trans	7.30%	Shs Float	28.82M	Perf Month	-44.34%
Income	-59.03M	PEG	-	EPS next Q	-	Inst Own	6.41%	Short Float	1.04%	Perf Quarter	77.44%
Sales	0.53M	P/S	32.45	EPS this Y	-	Inst Trans	0.08%	Short Ratio	1.23	Perf Half Y	-47.76%
Book/sh	-0.66	P/B	-	EPS next Y	-	ROA	-111.93%	Short Interest	0.30M	Perf Year	-55.28%
Cash/sh	0.04	P/C	11.62	EPS next 5Y	-	ROE	-1794.83%	52W Range	0.25 - 1.50	Perf YTD	0.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.89%	ROI	-	52W High	-66.61%	Beta	1.20
Dividend TTM	-	Quick Ratio	0.25	Sales past 5Y	56.81%	Gross Margin	-1283.77%	52W Low	100.36%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.25	EPS Y/Y TTM	-251.26%	Oper. Margin	-10356.79%	RSI (14)	41.47	Volatility	8.28% 22.06%
Employees	146	Debt/Eq	-	Sales Y/Y TTM	-98.53%	Profit Margin	-11138.11%	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-30.42%	Payout	-	Rel Volume	0.25	Prev Close	0.51
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-98.79%	Earnings	Apr 15 AMC	Avg Volume	244.61K	Price	0.50
SMA20	-18.62%	SMA50	-19.37%	SMA200	-25.82%	Trades		Volume	59,963	Change	-2.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-18	Initiated	Dawson James	Buy

Apr-15-24 05:07PM	Orgenesis Provides Year End Business Update (GlobeNewswire)
Apr-10-24 12:00PM	Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility (GlobeNewswire) +8.00%
Mar-18-24 08:30AM	Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference (GlobeNewswire) +11.00%
Mar-13-24 08:30AM	Orgenesis Consortium Awarded 1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes (GlobeNewswire)
Mar-04-24 08:30AM	Orgenesis Inc. Announces $2.3 Million Private Placement (GlobeNewswire) +12.65%
08:30AM	Loading…
Feb-29-24 08:30AM	Orgenesis Consortium Awarded 2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing (GlobeNewswire)
Jan-31-24 10:45AM	EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic (Benzinga)
09:15AM	Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic (GlobeNewswire)
Nov-14-23 08:30AM	Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM (GlobeNewswire)
Nov-13-23 04:15PM	Orgenesis Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -8.46%
Nov-08-23 09:00AM	Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering (GlobeNewswire) -10.46%
Nov-02-23 08:00AM	Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding (GlobeNewswire)
Oct-30-23 09:30PM	Orgenesis Announces Withdrawal of Proposed Public Offering (GlobeNewswire) -11.81%
04:07PM	Orgenesis Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-21-23 08:00AM	CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States (GlobeNewswire)
07:00AM	Loading…
Sep-06-23 07:00AM	Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support (GlobeNewswire) -7.88%
Aug-28-23 12:36PM	Is Orgenesis (ORGS) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) +36.34%
12:15PM	Orgenesis Inc (ORGS): A Deep Dive into Its Performance Potential (GuruFocus.com)
Aug-23-23 07:36PM	Orgenesis (ORGS): A Value Trap in Disguise? (GuruFocus.com) -19.89%
Aug-12-23 01:52AM	Q2 2023 Orgenesis Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-11-23 07:00AM	Orgenesis Provides Business Update for Second Quarter of 2023 (GlobeNewswire) +6.49%
Aug-10-23 08:30AM	Orgenesis Schedules Second Quarter 2023 Business Update Conference Call (GlobeNewswire)
Jul-13-23 08:30AM	Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer (GlobeNewswire)
Jul-11-23 07:00AM	Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera (GlobeNewswire)
Jun-15-23 06:51AM	Orgenesis Inc. (NASDAQ:ORGS) On The Verge Of Breaking Even (Simply Wall St.)
Jun-07-23 07:00AM	Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California (GlobeNewswire)
May-30-23 09:30AM	Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis (GlobeNewswire)
May-22-23 07:30AM	Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Masters Program (GlobeNewswire)
May-19-23 08:30AM	Orgenesis to Participate in Benchmarks 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023 (GlobeNewswire)
May-18-23 07:30AM	Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors (GlobeNewswire)
04:30PM	Loading…
May-10-23 04:30PM	Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy (GlobeNewswire)
10:00AM	Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary (GlobeNewswire)
Apr-25-23 08:30AM	Orgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy Manufacturing (GlobeNewswire)
Apr-19-23 02:48PM	Orgenesis Inc.'s (NASDAQ:ORGS) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
Mar-24-23 07:54AM	Orgenesis Inc. (NASDAQ:ORGS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 03:28AM	Q4 2022 Orgenesis Inc Earnings Call (Thomson Reuters StreetEvents) -6.29%
Mar-21-23 08:00AM	Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022 (GlobeNewswire)
Mar-17-23 09:00AM	Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call (GlobeNewswire) +18.11%
Mar-16-23 07:30AM	Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California (GlobeNewswire)
Feb-27-23 11:46AM	Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering (GlobeNewswire) +8.39%
Feb-23-23 09:55AM	Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering (GlobeNewswire) -32.37%
Jan-04-23 06:28AM	Investors in Orgenesis (NASDAQ:ORGS) have unfortunately lost 73% over the last five years (Simply Wall St.) +10.72%
Dec-20-22 08:00AM	Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model (GlobeNewswire)
Nov-16-22 05:53AM	Orgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-12-22 08:24AM	Loss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Nov-10-22 04:30PM	Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022 (GlobeNewswire)
08:30AM	Orgenesis Schedules Third Quarter 2022 Business Update Conference Call (GlobeNewswire)
Nov-07-22 08:30AM	Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services (GlobeNewswire) -8.63%
08:00AM	EXCLUSIVE: Orgenesis' Subsidiary Secures $50M Investment To Accelerate Point-of-Care Services Growth (Benzinga)
Aug-16-22 10:23AM	Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022 (GlobeNewswire) -5.35%
Aug-15-22 09:14AM	Orgenesis Schedules Second Quarter 2022 Business Update Conference Call (GlobeNewswire)
May-24-22 07:00AM	Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022 (GlobeNewswire) +11.90%
May-04-22 09:48AM	When Will Orgenesis Inc. (NASDAQ:ORGS) Breakeven? (Simply Wall St.)
May-03-22 06:30AM	Orgenesis Led Consortium Awarded 4M European Innovation Council Pathfinder Grant (GlobeNewswire) +10.76%
May-02-22 07:07AM	Hopkins partners with Maryland biotech Orgenesis on new cell therapy center (American City Business Journals) +5.33%
Mar-31-22 07:00AM	Orgenesis Inc. Announces $14.8 Million Private Placement (GlobeNewswire)
Mar-30-22 07:00AM	Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update (GlobeNewswire)
Mar-29-22 07:00AM	Orgenesis Schedules 2021 Fiscal Year Business Update Conference Call (GlobeNewswire) -5.90%
Mar-07-22 01:40PM	Orgenesis (NASDAQ:ORGS) shareholders are up 11% this past week, but still in the red over the last five years (Simply Wall St.) -7.56%
Jan-27-22 07:30AM	Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid (GlobeNewswire) +12.45%
Jan-18-22 07:30AM	Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing (GlobeNewswire) +6.49%
Nov-29-21 07:00AM	Orgenesis and Theracell Joint Venture to Receive up to 32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs (GlobeNewswire)
Nov-15-21 07:00AM	Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies (GlobeNewswire)
Nov-04-21 07:30AM	Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year (GlobeNewswire)
Nov-02-21 09:00AM	Orgenesis Schedules Third Quarter 2021 Business Update Conference Call (GlobeNewswire)
Aug-23-21 08:00AM	Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy Platform (GlobeNewswire)
Aug-16-21 08:30AM	Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 (ACCESSWIRE)
Aug-12-21 08:30AM	Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021 (ACCESSWIRE) -5.15%
Aug-05-21 07:00AM	Orgenesis Second Quarter 2021 Revenue Increases Over Six-Fold to $10.5 Million Compared to Second Quarter 2020 Reflecting Continued Progress of POCare Platform (GlobeNewswire)
Aug-03-21 08:30AM	Orgenesis Schedules Second Quarter 2021 Business Update Conference Call (GlobeNewswire)
Jul-26-21 07:56AM	Would Shareholders Who Purchased Orgenesis' (NASDAQ:ORGS) Stock Three Years Be Happy With The Share price Today? (Simply Wall St.)
Jul-06-21 07:00AM	Orgenesis Achieves Multiple Ranpirnase Development Milestones (GlobeNewswire)
Jun-15-21 03:23PM	Is Orgenesis Inc. (ORGS) A Good Stock To Buy? (Insider Monkey)
Jun-10-21 07:00AM	Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair (GlobeNewswire) +8.79%
Jun-01-21 07:30AM	Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd (GlobeNewswire)
May-27-21 07:15PM	35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 (ACCESSWIRE)
May-07-21 07:00AM	Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform (GlobeNewswire) +24.40%
May-06-21 07:30AM	FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection (GlobeNewswire)
May-05-21 07:30AM	Orgenesis Schedules First Quarter 2021 Business Update Conference Call (GlobeNewswire)
Mar-29-21 07:00AM	Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of Care Cell and Gene Therapy Center (GlobeNewswire)
Mar-18-21 07:00AM	Orgenesis Enters into Collaboration Agreement with MIDA to Deploy OMPULs for Point-of-Care Research and Development of Promising Cell and Gene Therapies (GlobeNewswire) -10.31%
Mar-11-21 07:00AM	Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy (GlobeNewswire)
Mar-09-21 08:08AM	The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data (Benzinga)
07:00AM	Orgenesis Provides Fiscal 2020 Year-End Results and Corporate Update; Expands POCare Therapeutic Pipeline, POCare Technologies, and POCare Network (GlobeNewswire)
Mar-08-21 07:30AM	Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea (GlobeNewswire)
Mar-04-21 11:15AM	Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call (GlobeNewswire)
Feb-16-21 07:00AM	Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-Side (GlobeNewswire) +6.22%
Jan-25-21 06:13AM	Is Orgenesis (NASDAQ:ORGS) Using Debt In A Risky Way? (Simply Wall St.) +5.66%
Nov-05-20 08:30AM	Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform (GlobeNewswire)
Nov-03-20 03:15PM	Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders (GlobeNewswire)
Oct-26-20 01:53PM	Did Orgenesis' (NASDAQ:ORGS) Share Price Deserve to Gain 44%? (Simply Wall St.)
Oct-19-20 06:30AM	Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction (GlobeNewswire)
Sep-29-20 06:30AM	Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies (GlobeNewswire)
Sep-09-20 07:00AM	Orgenesis CEO to Participate in Webinar Panel on New Approaches to COVID-19 on Thursday, September 10th (GlobeNewswire)
Aug-20-20 07:30AM	Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts (GlobeNewswire)
Aug-07-20 07:30AM	Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform (GlobeNewswire)
Aug-06-20 03:32PM	Health Check: How Prudently Does Orgenesis (NASDAQ:ORGS) Use Debt? (Simply Wall St.)
Jul-14-20 01:19PM	5 Health Care Stocks Trading With Low Price-Earnings Ratios (GuruFocus.com)
07:00AM	Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis Proprietary POCare Technologies for the Generation and Expansion of T-Cells (GlobeNewswire)
Jun-29-20 08:00AM	Orgenesis Added to Russell 3000® Index (GlobeNewswire) -5.17%

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Miller Victor	Chief Financial Officer	Apr 01 '24	Option Exercise	0.50	25,000	12,500	25,000	Apr 02 12:31 PM
Safier Jacob	10% Owner	Feb 01 '24	Buy	0.33	10,100	3,332	3,110,100	Feb 14 09:32 PM
Safier Jacob	10% Owner	Jan 31 '24	Buy	0.35	5,000	1,726	3,100,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 30 '24	Buy	0.33	25,000	8,245	3,095,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 26 '24	Buy	0.32	25,000	8,000	3,070,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 25 '24	Buy	0.32	25,000	7,920	3,045,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 22 '24	Buy	0.29	10,000	2,900	3,020,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 18 '24	Buy	0.33	10,000	3,309	3,010,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 11 '24	Buy	0.33	2,000	659	3,000,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Jan 10 '24	Buy	0.37	10,000	3,690	2,998,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Dec 21 '23	Buy	0.45	10,000	4,483	2,988,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Dec 12 '23	Buy	0.54	3,000	1,626	2,978,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Dec 11 '23	Buy	0.53	2,000	1,062	2,975,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Dec 01 '23	Buy	0.46	1,016	467	2,973,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 24 '23	Buy	0.54	5,000	2,701	2,971,984	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 21 '23	Buy	0.51	5,800	2,959	2,966,984	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 10 '23	Buy	0.58	1,184	688	2,961,184	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 09 '23	Buy	0.65	20,000	13,054	2,960,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 08 '23	Buy	0.71	20,000	14,188	2,940,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 02 '23	Buy	0.84	20,000	16,888	2,920,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Nov 01 '23	Buy	0.81	3,437	2,769	2,900,000	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 31 '23	Buy	0.74	5,000	3,690	2,896,563	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 27 '23	Buy	0.93	500	465	2,891,563	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 25 '23	Buy	0.88	500	438	2,891,063	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 24 '23	Buy	0.90	10,000	8,999	2,890,563	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 10 '23	Buy	0.86	603	519	2,880,563	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 06 '23	Buy	0.93	5,100	4,731	2,879,960	Feb 14 09:31 PM
Safier Jacob	10% Owner	Oct 05 '23	Buy	0.80	10,000	8,030	2,874,860	Feb 14 09:31 PM
Safier Jacob	10% Owner	Sep 28 '23	Buy	0.67	25,000	16,780	2,864,860	Feb 14 09:31 PM
Safier Jacob	10% Owner	Sep 21 '23	Buy	0.69	100,000	68,950	2,839,860	Feb 14 09:31 PM
Safier Jacob	10% Owner	Sep 07 '23	Buy	0.67	5,000	3,345	2,739,860	Feb 14 09:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORGS

Orgenesis Inc

Upgrade your FINVIZ experience